media – Page 584 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Janssen buys into Legend’s CART therapy

Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
- Source: Pharmatimes
- 412
- December 26, 2017
CAR-T therapy Company Insight Market Views
FDA clears Shire’s dosing software for haemophilia A SHARE

Irish biotechnology firm Shire has received 510(k) marketing clearance for its myPKFiT for ADVATE [Antihemophilic Factor (Recombinant)] software from the US Food and Drug Administration (FDA).
- Source: medicaldevice-network
- 603
- December 26, 2017
ADVATE FDA haemophilia A Shire
Seasonal flu kills up to 650,000 worldwide every year, study shows

Seasonal flu kills between 291,000 and 646,000 people worldwide every year, a new analysis of data from 47 countries suggested Wednesday.
- Source: news.mb
- 413
- December 26, 2017
Researches Seasonal flu
Health System CIOs Are Ready to Take mHealth to the Next Level

With some three-quarters of the nation’s health systems now having an mHealth communications strategy, CIOs are now setting their sights on integrating those platforms with clinical decision support tools, including the EHR.
- Source: mhealthintelligence
- 672
- December 25, 2017
CIO mHealth Researches
Clinicians still struggle to quickly access EHRs at point of care

Computers and workstations on wheels (WoWs) were designed to help clinicians spend less time working from nursing-station desktops and more time at the point of care. The reality, however, is that the ideal has yet to be fully realized. All too often care team workflows remain fragmented because of the need to access patient data and clinical information from multiple disparate systems.
- Source: healthcareitnews
- 474
- December 25, 2017
Clinical EHR Researches WoWs
What to know about allergy shots

Allergy shots are how allergen immunotherapy is commonly administered. This method is a proven way of treating reactions to allergens.
- Source: medicalnewstoday
- 549
- December 25, 2017
Allergy immunotherapy
Roche and Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.
- Source: Roche
- 529
- December 25, 2017
Ignyta Market Views Roche
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
- Source: Janssen
- 489
- December 25, 2017
CRPC inhibitor New Approvals
3 Amazing Advances in Pharmaceutical Drugs in 2017

As 2017 draws to a close, we look back at a year where advances in pharmaceutical drug therapies brought new hope to people from across the globe. These steps forward bring with them a sense of suspense as we wait for more ground-breaking work to be accomplished in 2018. Here is Drugdu.com’s list of medical advances that amazed.
- Source: Ddu
- 642
- December 25, 2017
Market Views pharmaceutical drugs
U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration(FDA) said, adding another competitor to a growing class of treatments.
- Source: Reuters
- 685
- December 25, 2017
ertugliflozin Merk New Approvals Pfizer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.